Brief: Grand Pharmaceutical Says Phase III Clinical Trial Of GPN00833 Conducted In China
04/11/2024 10:10
Nov 4 (Reuters) - Grand Pharmaceutical Group Ltd
0512.HK :
* PHASE III CLINICAL TRIAL OF GPN00833 CONDUCTED IN CHINA
HAS
COMPLETED AND SUCCESSFULLY MET CLINICAL ENDPOINT
Further company coverage: 0512.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement